XLO

Business Context and Reporting Period

Xilio Therapeutics, Inc. (XLO) is a clinical-stage biotechnology company developing tumor-activated immuno-oncology therapies. This Form 10-Q covers the quarterly period ended March 31, 2025. The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. As of May 5, 2025, there were 51,782,273 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Recognition: The company recognized $2.9 million in collaboration and license revenue in Q1 2025, compared to zero in Q1 2024. This was driven by the new collaboration agreement with AbbVie and the ongoing license agreement with Gilead.
• Operating Expenses: Total operating expenses decreased by $0.7 million to $16.8 million. Research and Development (R&D) expenses declined by $2.1 million, primarily due to the discontinuation of investment in the XTX202 monotherapy program and cost-sharing payments from Roche. General and Administrative (G&A) expenses increased by $2.4 million, driven by higher personnel costs and professional fees.
• Liquidity Position: Cash and cash equivalents increased significantly from $55.3 million at year-end 2024 to $89.1 million at March 31, 2025. This increase was fueled by a $42.0 million upfront payment from AbbVie, a $10.0 million equity investment from AbbVie, and $2.1 million from at-the-market offerings.
• Deferred Revenue: Deferred revenue liabilities increased substantially to $79.0 million (up from $32.8 million at year-end 2024) due to the upfront payments received from AbbVie and Gilead that are recognized over time.

Outlook, Risks, and Management Commentary

• Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern. Management estimates current cash resources will fund operations only into the first quarter of 2026. The company plans to raise additional capital through equity/debt financings or collaborations, but there is no assurance of success.
• Strategic Developments: In February 2025, Xilio entered a collaboration with AbbVie for up to four programs, receiving $52.0 million in total upfront consideration (cash and equity). The company also continues its Phase 2 trial for vilastobart in combination with atezolizumab and Phase 1 trial for XTX301.
• Nasdaq Compliance: On April 4, 2025, the company received a deficiency letter from Nasdaq regarding its stock price closing below $1.00 per share for 30 consecutive days. Xilio has 180 days (until October 1, 2025) to regain compliance or risk delisting.
• Risks: Key risks include the inability to secure additional capital, potential delisting from Nasdaq, reliance on third-party manufacturers (specifically WuXi Biologics in China), and the uncertainty of clinical trial outcomes for early-stage product candidates.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for the "first quarter of 2026" funding estimate and the company's immediate plans for capital raising given the "substantial doubt" disclosure.
• Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement to avoid delisting proceedings.
• AbbVie Agreement Terms: Review the specific milestones and performance obligations required to recognize the $79.0 million in deferred revenue.
• China Supply Chain: Assess the impact of U.S.-China trade tensions and potential legislation (e.g., BIOSECURE Act) on the company's reliance on WuXi Biologics for manufacturing.
• Program Prioritization: Confirm the status of the XTX202 program discontinuation and the resource reallocation to other pipeline assets like vilastobart and XTX301.